IISc spinout Venomics AI raises $2.7 million in pre-seed funding to expand its AI-powered Venom Atlas platform for venom-based drug discovery research.
OpenAI acquires biotech startup Orchestra Bio to expand its Rosalind platform with AI agents for drug development, clinical trial coordination and research workflows.
AstraZeneca partners with insitro in a deal worth up to $1.5 billion to use Virtual Human AI for discovering potential treatments for liver and heart diseases.
Anthropic CEO Dario Amodei predicts AI could help cure or prevent most diseases within five to 10 years, while biological data and clinical validation remain key hurdles.